Editor's Note
Welcome to the sixth issue of Xtalks Clinical Edge, where science, leadership and purpose converge!
This issue brings together 18 conversations with organizations advancing what’s possible in clinical research today. From neuroscience and oncology to cardiology, dermatology and rare diseases, each story reflects the shared goal of turning discovery into meaningful patient impact.
Across cardiovascular research, Bristol Myers Squibb highlights how global real-world evidence programs are transforming understanding of hypertrophic cardiomyopathy, while Medtronic examines a groundbreaking global trial exploring personalized pacing for heart failure.
Innovation in oncology and immunotherapy continues to accelerate. Boehringer Ingelheim explores how biomarker testing and precision oncology are transforming care in non-small cell lung cancer. Pyxis Oncology delves into the evolution of antibody-drug conjugates (ADCs) and CNS Pharmaceuticals suggests new strategies to overcome the blood-brain barrier in glioblastoma. Meanwhile, Actuate Therapeutics showcases how data-driven design may extend survival in pancreatic cancer, one of oncology’s toughest challenges.
Regarding precision medicine, Cerevance demonstrates how human brain data and AI are driving a new generation of precision neurology for Parkinson’s disease, while Faron Pharmaceuticals highlights how genomics and immune microenvironment research are reshaping trials in myelodysplastic syndrome.
In cell and gene therapy, FibroBiologics introduces a new research frontier with fibroblast-based therapeutics for immune modulation, wound healing and longevity, while Lineage Cell Therapeutics reflects on the growing maturity of regenerative medicine and the importance of in-house manufacturing to scale allogeneic cell therapies.
Several features show the power of data and collaboration in advancing equity and innovation. Chiesi Group explores how AI, real-world evidence and digital health are accelerating rare disease research, and Takeda shares how ethical, patient-centered trial design is shaping the future of rare disease drug development.
Lexicon Pharmaceuticals discusses the convergence of regulatory pragmatism and patient advocacy in clinical research, while UCB demonstrates how authenticity and inclusion are strengthening leadership in immunology and clinical trial diversity.
In dermatology, Galderma highlights how patient-reported outcomes and long-term real-world data are redefining clinical success, while in ophthalmology, Iolyx Therapeutics showcases how real-world trial designs are transforming the treatment landscape for dry eye disease.
We also spotlight emerging biotech ecosystems and the infrastructure shaping the future of innovation. The Chicago Biomedical Consortium shares how the Midwest is becoming a powerhouse for biotech translation and talent retention, while Ratio Therapeutics offers insight into the science and logistics driving next-generation radiopharmaceuticals.
At Xtalks Clinical Edge, our mission remains clear: to highlight the people, science and ideas moving clinical research forward.
We hope you enjoy this edition and join us again for our next issue in January 2026!